Key Takeaways:
Teva Pharmaceuticals agreed to align U.S. Medicaid prices with developed-market levels, joining nine drugmakers in deals covering 90 percent of the domestic pharmaceutical market.
"We appreciate the opportunity to work with President Trump and his Administration to expand access and affordability for patients today while enabling continued investment in medicines patients need tomorrow," Chris Fox, President of Teva USA, said.
The agreement, structured under the GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) framework, would align Teva's Medicaid pricing for select medicines with prices in leading developed markets. It also includes a prospective Most-Favored-Nation commitment for applicable future product launches. Teva has offered a dedicated reserve of certain active pharmaceutical ingredients for public health needs and committed to continued investment in U.S. pharmaceutical manufacturing. Negotiation conditions remain confidential and the agreement is not yet finalized.
The nine new agreements — with Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva and UCB — bring the Trump administration's total drug pricing deals to 26 companies, representing 90 percent of the domestic pharmaceutical market, the White House said. The companies collectively committed at least $19.6 billion to U.S. manufacturing in the near term. Teva, Astellas, Sun Pharma and UCB will together contribute 290 metric tons of active pharmaceutical ingredients to the federal strategic reserve, including 163 tons of the anticonvulsant levetiracetam from UCB.
The deals extend the administration's most-favored-nation policy, revived by executive order in May 2025, which links U.S. drug prices to the lowest prices paid in peer countries. U.S. prescription drug prices average nearly three times higher than overseas, according to a 2024 Rand Corp. study, with branded drugs more than four times higher. The administration estimates its broader drug pricing push could save $64.3 billion in federal and state spending over the next decade.
The agreements are voluntary and their terms remain private. PhRMA, the industry trade group, has said most-favored-nation pricing is not the best way to lower drug costs for Americans, instead blaming pharmacy benefit managers for the price disparity. Drugmakers are also weighing legal challenges to the administration's pricing policies.
Teva shares fell about 1 percent Monday, while most other signatories closed relatively flat. The deal could compress margins on select Medicaid drugs but provides regulatory certainty and strengthens Teva's relationship with the administration. Investors will watch for finalized terms and the impact on Teva's next quarterly earnings report.
This article is for informational purposes only and does not constitute investment advice.
